BioStem Technologies reported a significant earnings miss for Q1 2026, with a loss per share of $0.52 against a forecasted profit of $0.04. This led to a 14.88% drop in the company’s stock price in after-hours trading.
Revenue also fell short, with actual figures at $6.14 million compared to a forecast of $64.2 million. Despite this, hospital-based revenue showed resilience, reaching $5.4 million, consistent with the prior year.
The company is focusing on integrating its acquisition, expanding its sales force, and planning a technology transfer to improve margins. Full-year 2026 revenue guidance is set at $25–$29 million.
